Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dingdang Health Technology Group Ltd. (9886.HK)
HKD0.92
+0.00 (+0.00%)
CN HKSE Consumer Defensive Household & Personal Products
Description
Dingdang Health Technology Group Ltd. is a digital retail pharmacy firm operating within the People's Republic of China. The company provides online sales of pharmaceutical products alongside medical consultation services. Founded in 2014, it is based in Beijing, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD0.92
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.00
Float Shares
539.89M
Free Float %
43.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.75% | -7.78% | -21.70% | +0.00% | -23.15% | -22.43% | +72.92% | -62.44% | -93.08% | -93.08% | -93.08% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.92
DCF (Unlevered)
10.31
+1,020.9%
DCF (Levered)
11.19
+1,115.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.56
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Household & Personal Products: +3.3%+4.7% ★ Q4'25: +6.7% (vs Q4'24)
-
EPS growth Household & Personal Products: +8.8%+86.5% ★ Q4'25: +100.9% (vs Q4'24)
-
FCF margin FCF growth · Household & Personal Products: +44.8%-1.7% Q4'25: +7.0% (vs Q4'24)
-
EBIT margin Household & Personal Products: +9.9%-1.1% Q4'25: +0.3% (vs Q4'24)
-
ROIC Household & Personal Products: +8.2%-6.2% Q4'25: +0.9% (vs Q4'24)
-
Share dilution Household & Personal Products: +0.2%-1.8% ★ Q4'25: -1.9% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×-19.21× Q4'25: 6.54× (vs Q4'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
4.33B
est: 5.26B (-17.8%)
|
4.86B
est: 5.72B (-15.2%)
|
4.67B
est: 5.39B (-13.4%)
|
4.89B
est: 6.05B (-19.2%)
|
131.11B
131.11B – 131.11B
+2,066.6% YoY
|
165.86B
165.86B – 165.86B
+26.5% YoY
|
195.71B
195.71B – 195.71B
+18.0% YoY
|
| EBITDA |
-280.87M
est: -361.38M (+22.3%)
|
-73.35M
est: -392.99M (+81.3%)
|
-161.59M
est: 807.60M (-120.0%)
|
-15.83M
est: 906.21M (-101.7%)
|
19.63B
19.63B – 19.63B
+2,066.6% YoY
|
24.84B
24.84B – 24.84B
+26.5% YoY
|
29.31B
29.31B – 29.31B
+18.0% YoY
|
| EBIT |
-326.42M
est: -440.24M (+25.9%)
|
-213.35M
est: -478.74M (+55.4%)
|
-215.18M
est: 784.67M (-127.4%)
|
-53.44M
est: 880.47M (-106.1%)
|
19.08B
19.08B – 19.08B
+2,066.6% YoY
|
24.13B
24.13B – 24.13B
+26.5% YoY
|
28.48B
28.48B – 28.48B
+18.0% YoY
|
| Net Income |
-2.83B
est: -352.09M (-704.7%)
|
-225.81M
est: -237.15M (+4.8%)
|
-376.50M
est: -50.62M (-643.7%)
|
-49.02M
est: 12.98M (-477.7%)
|
-1.82B
-1.82B – -1.82B
-14,107.1% YoY
|
471.36M
471.36M – 471.36M
+125.9% YoY
|
1.21B
1.21B – 1.21B
+157.1% YoY
|
| SGA |
1.24B
est: 1.35B (-7.7%)
|
1.23B
est: 1.46B (-15.9%)
|
1.24B
est: 1.54B (-19.1%)
|
1.27B
est: 1.72B (-26.2%)
|
37.37B
37.37B – 37.37B
+2,066.6% YoY
|
47.27B
47.27B – 47.27B
+26.5% YoY
|
55.78B
55.78B – 55.78B
+18.0% YoY
|
| EPS |
-2.46
est: -0.27 (-824.0%)
|
-0.17
est: -0.18 (+5.2%)
|
-0.28
est: -0.04 (-618.2%)
|
-0.04
est: 0.01 (-477.2%)
|
-1.40
-1.40 – -1.40
-14,107.1% YoY
|
0.36
0.36 – 0.36
+125.9% YoY
|
0.93
0.93 – 0.93
+157.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
68.65M
OE per share TTM
0.05
Owner's Yield
6.37%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
6.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 1.4K | 0.42% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-22.6K
Shares Outstanding
1.25B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ning Xu | Vice President & Executive Director | 2M | male |
| Fanzhou Meng | Vice President & Executive Director | 2M | male |
| Qinglong Yu | CTO & Executive Director | 2M | male |
| Yibin Yang | Executive Director | 859.8K | male |
| Wenlong Yang | Executive Chairman & President | — | male |
| Yiu Por Lam | Chief Financial Officer & Joint Company Secretary | — | male |
| Zhenxuan Liu | Joint Company Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9886.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
